This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miró, E.
Right arrow Articles by Prats, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miró, E.
Right arrow Articles by Prats, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2002, p. 3991-3994, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3991-3994.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Prevalence of Clinical Isolates of Escherichia coli Producing Inhibitor-Resistant ß-Lactamases at a University Hospital in Barcelona, Spain, over a 3-Year Period

Elisenda Miró,* Ferran Navarro, Beatriz Mirelis, Montserrat Sabaté, Alba Rivera, Pere Coll, and Guillem Prats

Departament de Microbiologia, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma 08025 Barcelona, Spain

Received 3 May 2002/ Returned for modification 24 June 2002/ Accepted 16 September 2002

About 7% of 7,252 nonduplicated clinical Escherichia coli strains from a Spanish hospital showed reduced susceptibility to amoxicillin-clavulanate. Of these, 0.37% produced the IRTs TEM-30, TEM-31, TEM-33, TEM-34, TEM-37, TEM-40, TEM-51, and TEM-54; 5.3% were probable class C ß-lactamase overproducers; 0.8% were probable TEM-1 hyperproducers; 0.18% produced OXA-30; 0.15% overexpressed SHV-1; and 0.03% produced a PSE-1 enzyme.

* Corresponding author. Mailing address: Departament de Microbiologia, Hospital de la Santa Creu i Sant Pau, Av. Sant Antoni MaClaret, 167, 08025 Barcelona, Spain. Phone: 34 93 2919071. Fax: 34 93 2919070. E-mail: emiro{at}hsp.santpau.es.

Antimicrobial Agents and Chemotherapy, December 2002, p. 3991-3994, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3991-3994.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Aragon, L. M., Mirelis, B., Miro, E., Mata, C., Gomez, L., Rivera, A., Coll, P., Navarro, F. (2008). Increase in {beta}-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type {beta}-lactamases. J Antimicrob Chemother 61: 1029-1032 [Abstract] [Full Text]  
  • Chmelnitsky, I., Carmeli, Y., Leavitt, A., Schwaber, M. J., Navon-Venezia, S. (2005). CTX-M-2 and a New CTX-M-39 Enzyme Are the Major Extended-Spectrum Beta-Lactamases in Multiple Escherichia coli Clones Isolated in Tel Aviv, Israel. Antimicrob. Agents Chemother. 49: 4745-4750 [Abstract] [Full Text]  
  • Livermore, D. M., Hawkey, P. M. (2005). CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 56: 451-454 [Abstract] [Full Text]  
  • Hasman, H., Mevius, D., Veldman, K., Olesen, I., Aarestrup, F. M. (2005). {beta}-Lactamases among extended-spectrum {beta}-lactamase (ESBL)-resistant Salmonella from poultry, poultry products and human patients in The Netherlands. J Antimicrob Chemother 56: 115-121 [Abstract] [Full Text]  
  • Antunes, P., Machado, J., Sousa, J. C., Peixe, L. (2004). Dissemination amongst humans and food products of animal origin of a Salmonella typhimurium clone expressing an integron-borne OXA-30 {beta}-lactamase. J Antimicrob Chemother 54: 429-434 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»